(NASDAQ: TBPH) Theravance Biopharma's forecast annual revenue growth rate of 29.46% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 115.73%, and while it is forecast to beat the US market's average forecast revenue growth rate of 23.06%.
Theravance Biopharma's revenue in 2026 is $80,327,000.On average, 9 Wall Street analysts forecast TBPH's revenue for 2026 to be $5,207,605,734, with the lowest TBPH revenue forecast at $4,072,036,555, and the highest TBPH revenue forecast at $9,806,128,847. On average, 8 Wall Street analysts forecast TBPH's revenue for 2027 to be $6,145,045,707, with the lowest TBPH revenue forecast at $4,221,013,502, and the highest TBPH revenue forecast at $8,406,556,303.
In 2028, TBPH is forecast to generate $9,241,131,241 in revenue, with the lowest revenue forecast at $4,419,649,432 and the highest revenue forecast at $13,623,789,799.